BR112017002003A2 - biomarcadores de doença renal policística e usos dos mesmos - Google Patents

biomarcadores de doença renal policística e usos dos mesmos

Info

Publication number
BR112017002003A2
BR112017002003A2 BR112017002003A BR112017002003A BR112017002003A2 BR 112017002003 A2 BR112017002003 A2 BR 112017002003A2 BR 112017002003 A BR112017002003 A BR 112017002003A BR 112017002003 A BR112017002003 A BR 112017002003A BR 112017002003 A2 BR112017002003 A2 BR 112017002003A2
Authority
BR
Brazil
Prior art keywords
protein
drp
patient
kinase
phosphorylated
Prior art date
Application number
BR112017002003A
Other languages
English (en)
Portuguese (pt)
Inventor
Bukanov Nikolai
Beskrovnaya Oxana
Moreno Sarah
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BR112017002003A2 publication Critical patent/BR112017002003A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483Physical analysis of biological material
    • G01N33/487Physical analysis of biological material of liquid biological material
    • G01N33/49Blood
    • G01N33/492Determining multiple analytes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/60Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
BR112017002003A 2014-08-04 2015-08-03 biomarcadores de doença renal policística e usos dos mesmos BR112017002003A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462033031P 2014-08-04 2014-08-04
PCT/US2015/043497 WO2016022500A2 (en) 2014-08-04 2015-08-03 Biomarkers of polycystic kidney disease and uses thereof

Publications (1)

Publication Number Publication Date
BR112017002003A2 true BR112017002003A2 (pt) 2017-12-12

Family

ID=54035292

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017002003A BR112017002003A2 (pt) 2014-08-04 2015-08-03 biomarcadores de doença renal policística e usos dos mesmos

Country Status (12)

Country Link
US (1) US10871495B2 (https=)
EP (1) EP3177932B1 (https=)
JP (2) JP6730252B2 (https=)
KR (1) KR20170033436A (https=)
CN (1) CN106716136B (https=)
AU (1) AU2015301278A1 (https=)
BR (1) BR112017002003A2 (https=)
CO (1) CO2017001596A2 (https=)
MX (1) MX2017001648A (https=)
RU (1) RU2017106891A (https=)
SG (1) SG11201700290SA (https=)
WO (1) WO2016022500A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
GB201719520D0 (en) * 2017-11-24 2018-01-10 Univ College Cardiff Consultants Ltd Neuroprotectvie peptide
KR102859441B1 (ko) * 2019-11-22 2025-09-12 서울대학교산학협력단 Opn 검출용 제제를 포함하는, 다낭신의 진단용 조성물 및 이의 이용

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60039601D1 (de) 1999-05-24 2008-09-04 Avi Biopharma Inc Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
WO2006012394A1 (en) 2004-07-21 2006-02-02 Tulane University Health Sciences Center Treatment of renal dysfunction and multiple myeloma using pacap compounds
EP1808694A1 (en) 2006-01-17 2007-07-18 Universitätsklinikum Freiburg Method for diagnosing polycystic kidney disease
US20120077263A1 (en) * 2009-06-05 2012-03-29 Mayo Foundation For Medical Education And Research Methods and materials for isolating exosomes
CN102018702B (zh) * 2009-09-16 2012-07-18 北京大学 银杏内酯b的一种用途
WO2012042061A1 (en) * 2010-10-01 2012-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the progression and treating a chronic kidney disease in a patient
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
WO2014006093A1 (en) 2012-07-03 2014-01-09 Boletta Alessandra Compounds for use in polycystic kidney disease
MA37975B2 (fr) 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide

Also Published As

Publication number Publication date
CO2017001596A2 (es) 2017-05-19
AU2015301278A1 (en) 2017-02-09
RU2017106891A (ru) 2018-09-06
SG11201700290SA (en) 2017-02-27
US10871495B2 (en) 2020-12-22
JP7005695B2 (ja) 2022-02-04
CN106716136A (zh) 2017-05-24
WO2016022500A3 (en) 2016-04-07
JP2017525955A (ja) 2017-09-07
JP6730252B2 (ja) 2020-07-29
MX2017001648A (es) 2017-04-27
JP2020170013A (ja) 2020-10-15
KR20170033436A (ko) 2017-03-24
WO2016022500A2 (en) 2016-02-11
CN106716136B (zh) 2020-06-23
RU2017106891A3 (https=) 2019-03-14
EP3177932B1 (en) 2021-07-14
US20170227551A1 (en) 2017-08-10
EP3177932A2 (en) 2017-06-14

Similar Documents

Publication Publication Date Title
EP4365597A3 (en) Methods of assaying proteins
Lin et al. The crowding-out effect of formal insurance on informal risk sharing: An experimental study
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
BR112016007348A2 (pt) membro de ligação específica que se liga ao receptor do fator de crescimento epidérmico humano 2 (her2) para uso em um método de tratamento do câncer em um paciente, método de tratamento de câncer em um paciente, método de identificação de um câncer em um paciente, método para prognosticar a resposta de um câncer
BR112015023262A2 (pt) anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo
BR112016016937A8 (pt) partícula semelhante a vírus ou vírus, pluralidade de vírus isolados ou partículas semelhantes a vírus isoladas, ácido nucleico recombinante, célula adaptada a suspensão isolada, porção ligada a membrana da célula, célula adaptada a suspensão isolada, pluralidade de células adaptadas a suspensão isoladas, e método de identificação de um epítopo de célula t
BR112014018970A8 (pt) Dispositivos de coleta de amostra com agentes de estabilização sanguínea
BR112016004324A2 (pt) anticorpos
AR107078A1 (es) Anticuerpo antimiostatina, polipéptidos que contienen regiones fc variantes así como métodos de uso
BR112017025297A2 (pt) anticorpos anti-gitr para diagnóstico do câncer
BR112017023131A2 (pt) anticorpos anti- fcrn
WO2016015058A3 (en) Methods of determining tissues and/or cell types giving rise to cell-free dna, and methods of identifying a disease or disorder using same
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112014018729A8 (pt) Método e aparelho para testar materiais de circulação perdidos para formações subterrâneas
BR112013021657A2 (pt) método e sistema para isolar uma anomalia em potencial em dados de formação de imagem, e, meio legível em máquina
HK1258649A1 (zh) 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性
MX2024011859A (es) Biomarcadores de arn para angioedema hereditario
BR112019021352A8 (pt) Método para determinar e mitigar o risco de formação de cera de uma composição de hidrocarboneto, método para reduzir os riscos de formação de cera e sistema para uso de análise preditiva no gerenciamento de um processamento de hidrocarbonetos para determinar e mitigar a formação de cera
MX374415B (es) Composiciones y métodos para identificar un riesgo de cáncer en un sujeto.
BR112017002003A2 (pt) biomarcadores de doença renal policística e usos dos mesmos
BR112015031171A2 (pt) obtenção de um ligante terapêutico melhorado
BR112015002634A2 (pt) matriz e sistema para preservar espécimes biológicos para análise qualitativa e quantitativa.
BR112016024457A2 (pt) anticorpo isolado, imunoconjugado, uso do anticorpo, formulação farmacêutica, ácido nucleico isolado, célula hospedeira e método de produção de um anticorpo
BR112017002549A2 (pt) mutações em proteínas de grupos de ferro e enxofre que aperfeiçoam a utilização de xilose

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]